Contact Us
Location: Building 535Phone: (909) 607-9864
Email: diana_bartlett[at symbol]kgi.edu
China and the United States: Comparative Biotechnology Business, Law and Regulation
China is a burgeoning biotech market — but not one to be entered lightly.
Prepare yourself and your company to operate and compete in the China market by participating in KGI's three-day intensive course, "China and the US: Comparative Biotech Business, Law, and Regulation."
In this course, you will learn about:
- The development of the life science industry in the U.S and in China
- Creation of inventions in both countries and the workings of the U.S. Patent and Trademark Office and the Chinese State Intellectual Property Office
- An analysis of patent dispute resolution in both countries focusing on mediation, arbitration, adjudication in the courts, and administrative and customs enforcement
- An overview of the relevant business, governmental, university and non-profit players in both countries
- An understanding of the private and public fundraising efforts of companies in the U.S. and China
- An examination of the regulation of drugs, biologics and medical devices in the U.S. through the Food and Drug Adminstration and in China through the State Food and Drug Administration and a brief history of both organizations
- A comparative look at the state of research and development, manufacturing, distribution and corporate partnering in the U.S. and China
- An update on current government financing for life science companies in both countries
- A discussion of the ethical issues involved in managing the modern life science business in China and the U.S.
Who should attend?
Operations executives, finance managers, patent agents and attorneys, regulatory specialists, business development managers, R&D staff, human resources executives, and any other functional leaders charged with U.S./China involvement.
Faculty
The ChinaBio® program has been developed by Greg Scott and Randy Berholtz.
Scott is the president and founder of ChinaBio® LLC, a Shanghai-based investment and consulting firm, and president and co-founder of Life Science Angels, Inc, a U.S.-based investment group. He has helped launch 30 life science companies in the U.S. and China as a founder, investor or advisor. ChinaBio® holds four major life science conferences in China each year plus consults with a number of multinational pharma and biotech companies as well as venture capitalists.
Berholtz is an adjunct professor at KGI lecturing on biotechnology business law, an adjunct professor of law at the Thomas Jefferson School of Law, and a lecturer at the Rady School of Business at the University of California at San Diego. Berholtz is also the executive vice president and general counsel to Apricus Biosciences, Inc., a public drug delivery company in San Diego. He was formerly general counsel to a group of Chinese-U.S. life science companies and has represented numerous U.S. and China-based pharma, biotech and medical device companies. Berholtz is a graduate of Cornell, Yale Law School and Oxford University, where he was a Rhodes Scholar.
Venue
This class will take place at Keck Graduate Institute of Applied Life Sciences, 535 Watson Drive, Claremont CA 91711.
Schedule
Friday, May 20-Sunday, May 22: 8 am to 5 pm daily
Fee
The cost is $1,000/person, and includes lunch for all three days. KGI offers a 10% discount to groups of five or more from the same organization. Register before May 15, 2011.
Eligibility
This course is being offered as part of the ChinaBio® Life Sciences Summer Work-Study Program in Shanghai, China for the summer of 2011. Students enrolled in the ChinaBio® summer program must attend this three-day course held at KGI from May 20-22.
However, "China and the US: Comparative Biotech Business, Law, and Regulation" is not limited to ChinaBio® summer program participants only. This course is open to all interested individuals.